DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Rainbow Childrens Medicare Limited — Press Release

NSE 1 hr ago·31 Oct 2026, 2:25 pm

Rainbow Childrens Medicare

Rainbow Children's Medicare has informed the stock exchange that it will release its unaudited standalone and consolidated financial results for the quarter and half year ending September 30, 2026. The company has issued a press release on October 31, 2026, detailing these figures. This announcement marks the standard reporting cycle for the healthcare firm, providing a snapshot of its operational and financial health over the past six months.

For investors, this update is a key data point to gauge the company's performance amidst a competitive pediatric healthcare market. The results will reveal trends in revenue growth, operational efficiency, and profitability. Market participants will closely watch the consolidated figures to understand the group's overall standing, as this information is critical for assessing the stock's future trajectory and valuation.